Identified new, unknown at the ...

the provision of new, unknown in our earlier diagnostic categories (eg, panic disorder, dysthymia, schizotypal disorder, posttraumatic stress disorder, social phobia, etc.), requiring the use of special pharmacological approaches. Sixthly, scientific progress and new economic conditions led to the emergence of many new, little known to our physicians of generic drugs, advertising brochures which have reported very high or near-universal effectiveness. For the tradename often hides a well-known drug, reproduced or packed a small pharmaceutical company. Quality and bioavailability of such drugs often inferior products manufacturer, which is reflected in their clinical efficacy. The lack of an objective comparative information has caused some confusion in front of plenty of doctors available on the market of psychotropic drugs and a variety of indications for their use. Healthy conservatism and high costs often force doctors to avoid using unfamiliar drugs . The seventh feature is that a number of old drugs were discovered new evidence. For example, anticonvulsants (carbamazepine, valproic acid salt) became a means of preventing recurrence of affective psychosis, almost forgotten by doctors MAO inhibitors were more effective than tricyclic antidepressants for atypical depression and social phobia, and some tricyclic antidepressants (clomipramine) and selective serotonin reuptake inhibitors have been successfully applied in panic attacks, obsessive-compulsive, posttraumatic stress and other anxiety disorders. As the eighth stage of the development features of modern pharmacotherapy should mention the increase in the number of patients, when previously effective pharmacotherapy already is not enough efficient, which requires to the treatment of new drugs, the use of polypharmacy, with special protivorezistentnyh measures. In spite of the variety available in the market of psychotropic drugs and declared their high efficiency for various indications, almost every third patient is called, "no go" for therapy. And blame not only for developing adaptation to the drug or therapeutic effects of resistance, but mostly inept to use it. Specially performed in our clinic studies show that about 50% of cases of treatment failure due to its inadequate use. The most common errors, in addition to delays in starting treatment, as well as non-clinical indications and contraindications to the drug, are holding a template (without specific features) therapy in low doses or, conversely, frequent change, "juggling" drugs without complying with the required duration of exposure or premature removal of therapy. It is known that in many cases, the clinical effect develops gradually and suppression of current psychopathology does not necessarily mean the achievement of stable remission.